Thoracic aortic aneurysm (JAK2-associated)

Current understanding

Emerging scoping-review evidence suggests an association between JAK2-mutated MPNs and thoracic aortic aneurysm formation, extending the vascular complication profile of JAK2-driven disease beyond thrombosis into large-vessel wall pathology. Clinical implications for screening, surveillance, and management are not yet established; awareness during cardiovascular workup of JAK2-positive patients is the main current takeaway.

Evidence log

• 2026-09-03 — Targeting Thrombopoietin/MPL Signaling to Mitigate JAK2V617F-Driven Cardiac Microvascular Disease.: cross-connection with microvascular-symptoms: Both represent JAK2V617F-driven vascular pathologies beyond the classic peripheral microvascular syndrome — cardiac microvascular disease (TPO/MPL-mediated) and thoracic aortic aneurysm together suggest a broader JAK2-mutant vasculopathy spectrum warranting cardiovascular surveillance in MPN. (novelty: 4)
• 2025-11-20 — Splenic Artery Aneurysm Associated with Myelofibrosis Managed by Coil Embolization.: cross-connection with splenic-artery-aneurysm: Both represent MPN-associated arterial aneurysm complications, raising the question of a broader JAK2/MPN-driven vasculopathy across arterial beds. (novelty: 3)

Open questions

Related